

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/073618 A2

(51) International Patent Classification:
Not classified

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/075446

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
28 September 2023 (28.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/377,715 29 September 2022 (29.09.2022) US

(71) Applicant: ATALANTA THERAPEUTICS, INC.
[US/US]; 51 Sleeper Street, 7th Floor, Boston, MA 02210 (US).

(72) Inventors: GALLANT-BEHM, Corrie; 44 Mansfield Rd, Wellesley, MA 02481 (US). HASSLER, Matthew; 126 Border St, Apt 512, Boston, MA 02128 (US). CURTIS, Daniel; 57 Brettwood Rd, Belmont, MA 02478 (US). DA CRUZ GODINHO, Bruno, Miguel; 4 Fielding Rd, Reading, MA 01867 (US).

(74) Agent: QUARTARARO, Justin, S. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: SIRNA COMPOSITIONS AND METHODS TARGETING MICROTUBULE ASSOCIATED PROTEIN TAU NUCLEIC ACIDS

(57) Abstract: The instant application is directed to single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a microtubule-associated protein tau (MAP1) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5' phosphorus stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a tauopathy.



WO 2024/073618 A2